银发经济或成下一个风口(共8份)
银发经济或成下一个风口
-
艾媒咨询|2021年中国互联网医院行业发展研究报告
本报告涉及的案例/品牌/企业:医联,京东健康,好大夫
随着《健康中国2030规划纲要》、“互联网+医疗健康”的国家倡导和执行方针落实,中国互联网医院的数量在2015-2020年五年间增长近1000家,2021年进入稳定上升期。iMedia Research(艾媒咨询)数据显示,自2018年起,中国互联网医院行业进入以医院主导的互联网医院占多数的发展状态。医院主导和企业主导的互联网医院各有不同竞争优势,面对国家的规范政策和市场需求增长,通过差异化定位和院企合作能有效提升各方效益。
With the implementation of the national plan for health China 2030 and Internet plus medical health, the number of China's Internet hospitals increased by nearly 1000 in 2015-2020 years and five years, and entered a stable rise in 2021. According to the data of imedia research, since 2018, China's Internet hospital industry has entered a development state in which hospital led Internet hospitals account for the majority. Hospital led and enterprise led Internet hospitals have different competitive advantages. In the face of national normative policies and market demand growth, the benefits of all parties can be effectively improved through differentiated positioning and hospital enterprise cooperation. -
艾媒咨询|2021Q1中国保健品及NMN市场研究报告
本报告研究涉及企业/品牌/案例:汤臣倍健,健合集团,同仁堂,雅本化学,金达威
iiMedia Research (艾媒咨询)数据显示,随着国家人均GDP的提升,消费者在保健食品消费理念和消费意愿上都发生了根本性的转变,保健食品在消费属性上将逐渐从可选消费品向必选消费品转变,预计2021年中国保健品市场规模将增至2708亿元。在新冠疫情影响下,国民保健意识加速觉醒,居民消费观念升级,对保健品需求增加,为保健品行业带来长期利好。此外,市场对抗衰老产品需求的提升推动了NMN成分产品的走俏,预计到2023年将会以近70.25%的增速攀升至270.13亿元。
As the data of iiMedia Research showed, with the increase of the country's per capita GDP, consumers' consumption concept and willingness of health food have undergone fundamental changes. The consumption attribute of health food will gradually change from optional consumer goods to compulsory consumer goods. It is estimated that the market scale of health food in China will increase to 270.8 billion yuan in 2021. Under the influence of COVID-19, the awareness of national health care has been speeded up, the consumption concept of residents has been upgraded, and the demand for health products has increased, which has brought long-term benefits to the health care products industry. In addition, the increasing demand for anti-aging products in the market has promoted the popularity of NMN products, which is expected to rise to 27.013 billion yuan with a growth rate of nearly 70.25% by 2023. -
艾媒报告|2020-2021年中国医疗电商行业发展趋势及标杆企业分析报告
本报告研究涉及企业/品牌/案例:平安好医生,康爱多,阿里健康,健客,鱼跃医疗;其他提及企业/品牌:益药购,1药网,九州通网,心诺,我的医药网,好药师,美之氧,药京采,七乐康,欧姆龙,普天药城网,氧生活,未名企鹅,爱康多,巨人,药药好,京东大药房,康祝,药品终端网,360好药,可孚,药师帮,药房网,艾润科技,药便宜,八百方
2020年3月9日,全球知名的新经济产业第三方数据挖掘和分析机构iiMedia Research(艾媒咨询) 发布《2020-2021年中国医疗电商行业发展趋势及标杆企业分析报告》。报告根据艾媒数据中心、艾媒咨询商业情报数据库、艾媒商情舆情数据监测系统基础数据,对2020年中国医疗电商产业发展进行分析。本报告主要通过医药电商和家用医疗器械两方面,对医疗电商产业上下游深入探究运行模式,并对鱼跃集团、平安好医生、爱康多等典型企业进行案例分析,以此对中国医疗电商行业发展进行趋势预判。2019年中国医药电商行业发展规模继续增大,涌现出许多新型零售方式。越来越多医药企业涌入B2B主流市场,B2C市场规模也随着消费者健康意识的提升以及网购消费习惯的固定而得到较大发展;越来越多药企也开始开展O2O业务。以药到医、“医+药”发展的模式也受到普遍认可。特别在新型冠状病毒肺炎疫情影响下,医疗电商以其独特的互联网优势在抗击疫情中发挥了重要作用。在此契机下,医疗电商行业将在2020年迎来重大普及发展的历史机遇期。
In 2019, the scale of China's pharmaceutical e-commerce industry continues to increase, and many new retail methods have emerged. More and more pharmaceutical companies have entered the mainstream B2B market, and the scale of the B2C market has also grown significantly with the improvement of consumers' health awareness and the fixation of online shopping consumption habits; more and more pharmaceutical companies have begun to develop O2O business. The development model from medicine to medicine and "medicine + medicine" has also been widely recognized. Especially under the influence of the new coronavirus pneumonia epidemic, medical e-commerce has played an important role in fighting the epidemic with its unique Internet advantage. With this opportunity, the medical e-commerce industry will usher in a period of historical opportunities for significant popularization in 2020. -
艾媒报告 |2019全球及中国大健康产业运行大数据及决策分析报告
本报告研究涉及企业/品牌/案例:恒瑞医药,白云山,111集团,平安好医生,好大夫在线,优健康,春雨医生,微医,丁香医生,和美医疗,北大医疗,PHG,新氧,联合丽格,正广兴家庭医生,强森医疗,微脉,美中嘉和,零氪科技,中有精准医疗,思派网络,普瑞眼科,臻和科技,移宇科技,小鹿医馆,妈咪知道,八百方,京东医药,阿里健康大药房,1药网,一心堂,健一网,好药师,健客网,美丽神器,更美,悦美,美莱整形,伊美尔,丽都整形,芝星整形,欧华美科
大健康产业细分领域的垂直深化,推动了大健康产业格局的不断完善。受政策鼓励和资本推动的影响,2019年,大健康产业在患者服务类领域、医疗服务类领域、医药服务类领域、医疗美容类领域和医疗保健类领域等细分场景快速发展。以恒瑞医药、白云山为代表的传统医药上市公司和以平安好医生、111集团和新氧科技为代表的互联网医疗上市企业各自占据大健康产业领域的一席之地。艾媒商情舆情监测系统数据显示,受2018年和2019年上半年医疗领域负面舆情的影响,大健康产业各上市企业正从低谷平稳回升。艾媒咨询分析师认为,受社会医疗需求和国家政策的推动,大健康产业仍是未来投资的亮点。
The vertical deepening of the large health industry segment has promoted the continuous improvement of the pattern of the big health industry. Influenced by policy encouragement and capital promotion, in 2019, the big health industry developed rapidly in the sub-sectors such as patient service, medical services, medical services, medical and beauty, and health care. The traditional pharmaceutical listed companies represented by Hengrui Medicine and Baiyun Mountain and the Internet medical listed companies represented by Ping An Doctor, 111 Group and New Oxygen Technology each occupy a place in the field of large health industry. According to data from the Aibu Business Intelligence Monitoring System, the listed companies in the big health industry are recovering steadily from the bottom of the market due to the negative public sentiment in the medical field in the first half of 2018 and 2019. Ai Media Consulting analysts believe that the health industry is still the highlight of future investment, driven by social medical needs and national policies. -
艾媒报告 |2019全球与中国医药电商市场与发展趋势研究报告
本报告研究涉及企业/品牌/案例:天猫医馆,七乐康,京卫大药房,阿里健康大药房,京东大药房,健客, 1药网,360好药,八百方,818医药网,CVS,Walgreens ,RiteAid ,开心人网上药店,药房网,药材买卖网,珍材网,中药材天地网,商康网,科欣医药,医药在线,我的医药网,药品交易网,药品终端网,药师帮,海王晨星,快方送药,药给力,搜药送,药急送,U医U药,叮当送药,健客网上药店,康爱多掌上药店,问药,好药师,111集团,中宏保险,医联,腾讯,仁和药业,浙江扁鹊,漱玉平民,华人健康,一树药业,德生堂
2019中国医药电商主要形成了B2C、B2B、O2O三种模式,B2C模式体量稳定在6%左右,规模呈增长趋势,预计2019年的市场交易额将达到554.6亿元;B2B模式下,西药类产品的需求比例较高,达87.1%,中药材、传统药品和第三方交易等都形成了专属B2B平台;而近几年兴起的O2O模式,主要通过“引流-转化-消费-反馈”等实现盈利,但区域覆盖度和消费者的信任度需要提高。iiMedia Research(艾媒咨询)大数据监测显示,目前1药网、健客网上药店、康爱多掌上药店的的综合实力排行较强。
2019 China's pharmaceutical e-commerce mainly formed three modes of B2C, B2B and O2O. The volume of B2C model is stable at around 6%, and the scale is increasing. It is expected that the market transaction volume in 2019 will reach 55.46 billion yuan; in B2B mode, western medicine The demand ratio of products is relatively high, reaching 87.1%. Chinese herbal medicines, traditional medicines and third-party transactions have formed a proprietary B2B platform. In recent years, the O2O model has emerged mainly through “drainage-conversion-consumption-feedback”. Achieve profitability, but regional coverage and consumer trust need to be improved. iiMedia Research (Ai Media Consulting) big data monitoring shows that the current comprehensive strength of 1 drug network, Jianke online pharmacy, Kang Aiduo pharmacy is strong. -
艾媒报告|2019中国保健品行业发展困境及前景预判分析报告
本报告研究涉及企业/品牌/案例:Blackmores、Swisse、Bioisland、汤臣倍健、脑白金、黄金搭档、纽崔莱、东阿阿胶、安利、养生堂、九芝堂、无极限、权健、健合集团、天猫、京东、太太、碧生源、袋鼠电商、恩馨国际、萨拜、嗨侬实业、姜之燕燕窝、泡范儿、健康优选、呀苹果、乐年商城
报告摘要
电商渠道逐渐成为中国营养保健品行业增长新引擎。然而,目前保健品行业的负面舆情相对较多,负面舆情爆发促使中国政府加大行业监管力度。例如,中国政府颁布了《国务院关于深化改革加强食品安全工作的意见》《国务院办公厅关于推进养老服务发展的意见》,表示将全面开展严厉打击保健食品欺诈和虚假宣传、虚假广告等违法犯罪行为,并实施保健食品行业专项清理整治行动;中国药监局逐渐减少保健食品生产许可证的发放数量,营养保健品行业准入门槛提高。保健品龙头企业发展相对平稳,2018年,中国营养保健品巨头汤臣倍健收购了Life-Space和Penta-vite,全年营收43.5亿元,同比增长39.9%,但负面舆情爆发损害品牌形象。
E-commerce has gradually become a new growth engine for China's health care products industry. However, there are relatively more negative public opinions on the health care products industry and the outbreak of negative public opinions urges the Chinese government to strengthen the supervision of the industry. For example, the Chinese government promulgated the ““The state council’s opinion on deepening reform to strengthen food safety work ““, ““The general office of the state council’s opinion on promoting the development of the endowment service ““, says it will launch a crackdown on health food fraud ,false advertising, and false advertising, and implement special clean-up actions; China's food and drug administration has gradually reduced the number of health food production licenses issued, and the entry threshold for health food industry has been raised. In 2018, By-Health, a leading enterprise of Chinese health products industry, purchased Life-space and Penta-vite, and its annual revenue reached 4.35 billion yuan, up 39.9% year on year, but the outburst of negative public opinions damaged the brand image. -
艾媒报告 |2019中国人造肉产业研究与消费者行为调查报告
本报告研究涉及企业/品牌/案例:Beyond Meat,Impossible Foods,杜邦,Ripple Foods,Bolthouse Farms,Roquette,Field Roast,Gardein,Mosa Meat,Modern Meadow,Finless Foods,烟台双塔食品,深圳齐善食品,宁波素莲素食,江苏鸿旭食品,万达财富,来伊份,登海种业,大北农,新开疆,京粮控股,四环生物,九芝堂,ST天宝,友好集团,爱普股份,丰乐种业,北大荒,天士力,中源协和,大康农业,东宝生物,融捷健康,华宝股份,戴维医疗,千红制药,金健米业,圣济堂,济民制药,哈高科,国际医学,维维股份,海欣食品,复星医药,苏常柴A,瑞茂通
人造肉主要包括植物肉、培育肉和混合肉三类。随着全球肉类短缺危机、健康与环保的消费风潮、食品创新推动等因素带动人造肉产业发展,资本市场开始关注人造肉产业,例如,Beyond Meat上市股市表现良好,Impossible Foods已完成超过6.875亿美元的多轮融资。中国的人造肉市场也开始发展,艾媒商情舆情数据监测系统显示,广东网民最关注人造肉议题。在资本和舆论的带动下,A股市场人造肉版块的活跃,同时,各类人造肉的上游产业链如大豆、豌豆蛋白、胎牛血清等开始共同发展。iiMedia Research(艾媒咨询),36%的中国消费者并不了解人造肉,同时低于四成消费者愿意尝试人造肉。艾媒咨询分析师认为,人造肉要真正市场化普及仍需克服成本、技术、消费者心理因素等多重障碍。
Artificial meat mainly includes three types of plant meat, cultivated meat and mixed meat. With the global meat shortage crisis, the consumption trend of health and environmental protection, and the promotion of food innovation, the capital market has begun to focus on the artificial meat industry. For example, Beyond Meat listed stocks performed well, and Impossible Foods has completed more than 687.5 million. Multiple rounds of financing for the dollar. China's artificial meat market has also begun to develop, and the iiMedia Research business data analysis system shows that Guangdong netizens are most concerned about artificial meat issues. Driven by capital and public opinion, the artificial meat section of the A-share market is active. At the same time, the upstream industrial chains of various types of artificial meat, such as soybean, pea protein and fetal bovine serum, have begun to develop together. iiMedia Research, 36% of Chinese consumers do not know about artificial meat, and less than 40% of consumers are willing to try artificial meat. Ai Media Consulting analysts believe that the real marketization of artificial meat still needs to overcome multiple obstacles such as cost, technology and consumer psychological factors. -
艾媒报告 |2019年中国生物医药产业发展及舆论焦点分析报告
本报告研究涉及企业/品牌包括:Takeda、GSK、Sanofi、Celgene、Novartis、宝洁、CVC Fund VII、Shire、诺华OTC、Bioverativ、Juno Therapeutics、AveXis、Impact Biomedicines、Tesaro、Ablynx、默克OTC、Recordati控股公司FIMEI、复星医药、海正药业、康弘药业、泰合健康、齐鲁制药、复宏汉霖、信达生物、张江生物、恒瑞医药、三生国健、嘉和生物、百奥泰、深圳龙瑞、天坛生物、华兰生物、博雅生物、上海莱士、卫光生物、辽宁成大、智飞生物、康泰生物、沃森生物、利德曼、交大昂立、华润双鹤、力生制药、海欣股份、联环药业、白云山、中源协和、普洛药业
随着生物医药技术不断突破,中国生物医药产业快速发展,2018年,单抗、血液制品、疫苗等生物医药相关领域多家头部上市企业营收均超亿元,实现同比增长。iiMedia Research(艾媒咨询)监测发现,生物医药产业网络言值指数为49.7,网民评价态度偏向正面,上海网民对生物医药产业的关注度最高。未来,随着中国生物医药行业上市公司数量增多,行业与企业间竞争将更加激烈。
The scale of China's bio-pharmaceutical industry continues to grow, and the proportion of bio-pharmaceutical output in the pharmaceutical industry continues to rise. In 2017, the total output value of the bio-pharmaceutical industry in China's park was about 1.5 trillion yuan. At present, China's biomedical industry has formed three major clusters, including the Bohai Rim region, the Yangtze River Delta region and the Pearl River Delta region, and the industrial agglomeration effect is outstanding. China's bio-pharmaceutical industry is in a stage of rapid development. In 2018, many head-to-head listed companies in biomedical related fields such as monoclonal antibodies, blood products and vaccines all exceeded 100 million yuan, achieving year-on-year growth. According to iiMedia Research, netizens in Shanghai are most concerned about the biomedical industry, and 40.9% of netizens surveyed support the application of transgenic technology in the pharmaceutical field. Among the heads of monoclonal antibodies, blood products and vaccines, Fuhong Hanlin as well as Weiguang Bio and Lidmanthe has the best online reputation,iiMedia Consulting analysts believe that in the future, the combination of artificial intelligence with new drug research and the fierce competition among head enterprises is an important trend in the development of China's biomedical industry.
- 1
- 2
没找到想要的报告?
扫码添加客服参与预约/定制,第一时间获取行业推荐报告!
智库热榜
艾媒咨询|2024-2025年中国银发经济投资前景分析报告
艾媒咨询|2024-2025年中国烘焙食品行业现状及趋势研究报告
艾媒咨询 | 2023-2024年中国休闲食品产业现状及消费行为数据研究报告
艾媒咨询|2024-2025年全球及中国新能源汽车行业消费趋势监测与案例研究报告
艾媒咨询 | 2023-2024年中国全域旅游产业运行数据及发展趋势研究报告
艾媒咨询 | 2024年中国家用美容仪行业消费者洞察研究报告
艾媒咨询|赵一鸣零食店消费行为洞察及行业趋势报告(2024)
艾媒咨询|2024年中国月饼行业创新发展研究报告
艾媒咨询 | 2024年中国数字中台市场研究报告
艾媒咨询|2023-2024年全球及中国跨境电商运营数据及典型企业分析研究报告
艾媒咨询|2024年中国家清产品消费趋势洞察报告